Literature DB >> 17577124

Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients.

Romain Micol1, Olivier Lortholary, Borann Sar, Didier Laureillard, ChanChhaya Ngeth, Jean-Philippe Dousset, Hak Chanroeun, Laurent Ferradini, Philippe Jean Guerin, Françoise Dromer, Arnaud Fontanet.   

Abstract

OBJECTIVES: To determine the prevalence, determinants ofpositivity, and clinical utility of serum cryptococcal polysaccharide (CPS) antigen testing among HIV-infected patients in 2004 in Cambodia, an area highly endemic for cryptococcosis.
METHODS: All HIV-infected patients with a CD4+ count <200 cells/mm3 attending 1 of 2 Phnom Penh hospitals for the first time were systematically screened for serum CPS. Patients with positive test results were further investigated to identify those with cryptococcal meningitis (CM), pulmonary cryptococcosis, or isolated positive cryptococcal antigenemia (IPCA).
RESULTS: The median (interquartile range [IQR]) CD4+ count of 327 enrolled patients was 24 (IQR: 8 to 65) cells/mm3. The prevalence of cryptococcal infection was 59 (18.0%) of 327 cases, of which 41 were CM and 10 were IPCA. In the absence of serum CPS detection, 17 (28.8%) of 59 cryptococcal infections would have been missed on the day of consultation. In patients with no specific symptoms of meningoencephalitis, the prevalence of positive serum CPS detection was 32 (10.8%) of 295 cases. Countryside residence (adjusted odds ratio [AOR] = 3.6), headache (AOR = 3.2), body mass index <15.4 kg/m2 (AOR = 3.4), CD4+ count <50 cells/mm3 (AOR = 4.0), and male gender (marginally, AOR = 2.1) were all independently associated with a positive test results.
CONCLUSION: Serum CPS screening among AIDS patients with a CD4+ count <100 cells/mm3 is useful in areas highly endemic for cryptococcosis, allowing early diagnosis and treatment of this opportunistic infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17577124     DOI: 10.1097/QAI.0b013e31811ed32c

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  52 in total

1.  Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda.

Authors:  Alfred O Andama; Saskia den Boon; David Meya; Adithya Cattamanchi; William Worodria; J Lucian Davis; Nicholas D Walter; Samuel D Yoo; Nelson Kalema; Barbara Haller; Laurence Huang
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

2.  Screening for cryptococcal antigenemia in anti-retroviral naïve AIDS patients in benin city, Nigeria.

Authors:  Favour Osazuwa; John Osilume Dirisu; Patrick Evbaguehita Okuonghae; Ose Ugbebor
Journal:  Oman Med J       Date:  2012-05

3.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

4.  Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques.

Authors:  V Cecchinato; C J Trindade; A Laurence; J M Heraud; J M Brenchley; M G Ferrari; L Zaffiri; E Tryniszewska; W P Tsai; M Vaccari; R Washington Parks; D Venzon; D C Douek; J J O'Shea; G Franchini
Journal:  Mucosal Immunol       Date:  2008-05-07       Impact factor: 7.313

5.  Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia.

Authors:  Romain Micol; Ayden Tajahmady; Olivier Lortholary; Suna Balkan; Catherine Quillet; Jean-Philippe Dousset; Hak Chanroeun; Yoann Madec; Arnaud Fontanet; Yazdan Yazdanpanah
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

6.  Utility of clinical assessment, imaging, and cryptococcal antigen titer to predict AIDS-related complicated forms of cryptococcal meningitis.

Authors:  Edward R Cachay; Joseph Caperna; Amy M Sitapati; Hamta Jafari; Sean Kandel; William C Mathews
Journal:  AIDS Res Ther       Date:  2010-08-03       Impact factor: 2.250

Review 7.  Asymptomatic cryptococcemia in resource-limited settings.

Authors:  Ana-Claire Meyer; Mark Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

8.  CrAg lateral flow assay for cryptococcosis.

Authors:  Thomas R Kozel; Sean K Bauman
Journal:  Expert Opin Med Diagn       Date:  2012-04-19

9.  Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.

Authors:  Joseph N Jarvis; Stephen D Lawn; Monica Vogt; Nonzwakazi Bangani; Robin Wood; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

10.  Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen.

Authors:  Nina Singh; Barbara D Alexander; Olivier Lortholary; Françoise Dromer; Krishan L Gupta; George T John; Ramon del Busto; Goran B Klintmalm; Jyoti Somani; G Marshall Lyon; Kenneth Pursell; Valentina Stosor; Patricia Muñoz; Ajit P Limaye; Andre C Kalil; Timothy L Pruett; Julia Garcia-Diaz; Atul Humar; Sally Houston; Andrew A House; Dannah Wray; Susan Orloff; Lorraine A Dowdy; Robert A Fisher; Joseph Heitman; Marilyn M Wagener; Shahid Husain
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.